TG Therapeutics sells Briumvi, a once-a-year infusion for relapsing multiple sclerosis, plus a pipeline of cancer drugs targeting B-cell malignancies.
Revenue hit USD 0.62B in 2025 with gross margin near 84%, driven by recurring Briumvi sales; net margin jumped to 72.6% on a one-time gain.
Briumvi's differentiated dosing and efficacy create switching costs, but Roche's Ocrevus and Novartis's Kesimpta dominate the MS market, pressuring adoption.
Hold (sector percentile 55) — value B-, growth B, profitability A, momentum B+, revisions D. Updated daily, sector-relative, identical for every user.
Key events, in time order
Institutional 13F filing shows significant stake increase, reflecting fund positioning
Q2 revenue $240M beat, EPS $0.05 miss, but BRIUMVI strength raises FY guidance to $950M
Multiple sources confirm earnings timing, market awaits results
Multiple independent X accounts list TGTX in IBD Top 15 and short-pain lists, indicating heightened attention
U.S. BRIUMVI net product revenue in Q1 2026 was approximately $195 million, exceeding guidance of $185 million to $190 million, with 63% year-over-year growth
None yet
None yet
Analysts are increasing revenue and price targets for TG Therapeutics ($TGTX) due to anticipated growth from a new subcutaneous formulation of Briumvi and its potential to capture a new market segment.
Main discussion
Different voices
$TGTX Cowen updated $TGTX model -increased Briumvi revenue estimates for 2028+ to account for anticipated launch of a SC Briumvi formulation, resulting in new peak revenue estimate of $5.3B in 2035 (vs. the prior $3.5B) & $12 EPS also increase DCF-based PT to $75 (vs. the prior $
$TGTX Jeffries Upside Scenario, 6.8 Billion $98, +84% • IV Briumvi: US peak penetration of 35% in RMS and peak sales of ~$2.6B • SC Briumvi: 100% POS for US peak penetration of 35% and peak sales of ~$4.2B
$TGTX is definitely older #Biotech been around - too many investors have not given it fresh look - SUBq is next growth driver & doubles sales estimates starting 2028. - •SubQ market is already 35-40% of CD20 market where TG does not currently compete,but with a quarterly dosing o
$TGTX - Cantor Prakwar who has one better models on $TGTX gives TG credit for patent protection of the Briumvi franchise into the early 2040s assume peak sales of 4B, DCF yields a valuation of $80-$85/sh. With many upside levers along the way
RT @MattBiotech: Published today on $TGTX, the three piece of great news for the company in the past few weeks, and how my model has a targ…
RECAP 8/21 Chatter: $TGTX + $JAZZ $CLF + $500M DOE award $HSAI - US Gov probe RECAP 8/21 +Pos Comments: $MOD + Hunterbrook $FLNT + Singular Research RECAP 8/21 -Neg Comments: $AFRM - BTIG Live Breaking trading news http://www.openoutcrier.com
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
